Roche granted breakthrough status for liver cancer combo
Roche announced today that the US-American Food and Drug Administration FDA has granted Breakthrough Therapy designation for the Swiss pharma giants mAb combination therapy for liver cancer.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 234 entries already.
Entries by Uta Mommert
Epigenetic biomarkers predict immunotherapy success
UK biotech Oxford BioDynamics has presented data showing that the companys blood test can predict patient response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1.
Urovant launches US$150m IPO
Swiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron.
Immunooncology: Genmab teams up with Immatics
Danish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications.
Big Data: Tracking cancer risk genes
Using only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk.
Lifecare floats on Oslo stock exchange
Norwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor.
Abingworth closes new biotech fund at €268m
Bioscience investment firm Abingworth has closed its latest fund at US$315m (€268m). The money will go to life sciences companies in Europe and the US.
€47m for rare disease biotech
After €7m went to Nextbiotix last week, another financing round is bringing money to a young French biotech. Strasbourg-based Dynacure attracted €47m from investors to bring its lead candidate for centronuclear myopathy into clinical development.
€7m for French microbiome start-up
Microbiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases.
Highs and lows for Fresenius Medical Care
Dialysis product and service provider Fresenius Medical Care has placed €500m notes. Yesterday, the medtech giant had to come to terms with a sharp drop in share price.